Part 1, Independent top researchers who have shown high efficacy for nanoviricides:
Dr Eva Harris, Professor, Division of Infectious Diseases and Vaccinology; Director, Center for Global Public Health
Research Description:
Dr. Harris has developed a multidisciplinary approach to study the molecular virology, pathogenesis, immunology, and epidemiology of dengue, the most prevalent mosquito-borne viral disease in humans. Her work investigates the mechanism of dengue virus translation and replication and host cell-virus interactions, as well as viral and host factors that modulate disease severity. One major research focus has been the development of a mouse model to study viral tropism and pathogenesis, investigate the immune response to dengue virus infection, and generate a better model of disease. This has resulted in a mouse model for antibody-dependent enhancement of dengue disease that is being used to dissect antibody determinants of protection, enhancement, and therapeutic efficacy and to test different classes of candidate antiviral compounds. Her field work focuses on laboratory-based and epidemiological studies of dengue and influenza in endemic Latin American countries.
Results of Initial Results Dengue Hemorrhagic Fever Treated with nanoviricide injection alone:
Results of the study demonstrated a 50 percent survival rate of the animals in the ADE model; additionally, the length of survival of animals treated with several Dengue nanoviricides surpassed the length of survival for animals treated with the vehicle alone.
“We are very excited about these results,” Dr. Harris stated. “This is a very important demonstration of a viable drug candidate leading to significant survival in the ADE model of Dengue virus infection. I believe nanoviricides show great promise in our model and against severe dengue disease.”
News 
Market Data 
Discover 
